Valsartan Loaded Solid Lipid Nanoparticles: Development, Characterization, and In vitro and Ex vivo Evaluation

DOI:

https://doi.org/10.37285/ijpsn.2011.4.3.7

Authors

  • Krutika K Sawant
  • B Parmar
  • S A Mandal
  • K C Petkar
  • L D Patel

Abstract

Valsartan is an antihypertensive drug with poor oral bioavailability ranging from 10-35% because of poor solubility, dissolution and most importantly, extensive first pass hepatic metabolism. The present study deals with the development and characterization of Valsartan-loaded solid lipid nanoparticles (VSLNs) to enhance the solubility, bypass the first pass hepatic metabolism, and enhance the lymphatic absorption leading to improved bioavailability. VSLNs were developed using glyceryl behenate (Compritol 888 ATO®) as the lipid and Poloxamer 407 (Pluronic F 127) as the surfactant by the solvent injection method. VSLNs were characterized for mean particle Size (MPS), zeta potential, percentage drug entrapment (PDE), DSC Scans, XRD and TEM analysis. In vitro drug release studies were performed in 0.067 M phosphate buffer of pH 6.8 using dialysis diffusion bag method. Ex vivo drug release studies were also performed for both VSLNs and valsartan suspension in stomach and intestine. The optimized formulation of having the 80 mg lipid, 10 mg drug and 250 mg surfactant was found to have particle size distribution of 142.5 ± 1.859 nm, zeta potential of – 14.3 ± 0.384 mV, and 84.59 ± 0.328% drug entrapment. Based on these results, it is concluded that SLNs show promise for improving the oral bioavailability of valsartan. 

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Keywords:

Valsartan, poor solubility, oral bioavailability, first-pass metabolism, lymphatic absorption, solvent injection method.

Downloads

Published

2011-11-30

How to Cite

1.
Sawant KK, Parmar B, Mandal SA, Petkar KC, Patel LD. Valsartan Loaded Solid Lipid Nanoparticles: Development, Characterization, and In vitro and Ex vivo Evaluation. Scopus Indexed [Internet]. 2011 Nov. 30 [cited 2024 Dec. 11];4(3):1483-90. Available from: https://www.ijpsnonline.com/index.php/ijpsn/article/view/441

Issue

Section

Research Articles

References

Amidon GL and Lobenberg R (2000). Modern bioavailability, bioequivalence and biopharmaceutics classification system: new scientific approaches to international regulatory standards. Eur J Pharm Biopharm 50: 3-12.

Babasaheb A and Pravin N (2009). Solid state characterization of the inclusion complex of valsartan with methyl β-cyclodextrin. J Incl Phenom Macrocycl Chem 65: 377–383.

Brookman LJ, Benjamin IS and Rolan PE (1997). Pharmacokinetics of valsartan in patients with liver disease. Clin Pharmacol Therap 62(3): 272-278.

Brunella C, Clelia DM and Maria IA (2006). Improvement of solubility and stability of valsartan by hydroxypropyl-beta-cyclodextrin. J Incl Phenom Macrocycl Chem 54: 289-94.

Cerulli A, Frech FH and Smith DG (2005). Use of valsartan for the treatment of heart-failure patients not receiving ACE inhibitors: a budget impact analysis. Clin Pharmacol Therap 27(6): 951 - 959.

Chandrasekhar D, Ramakrishna S and Vinay Kumara V (2007). Development and evaluation of nitrendipine loaded solid lipid nanoparticles: Influence of wax and Glyceride lipids on plasma pharmacokinetics. Int J Pharma 335: 167– 175.

Charman WN and Porter CJH (1996). Lipophilic prodrugs designed for intestinal lymphatic transport. Adv Drug Delivery Rev 19: 149–169.

Charman WN and Porter CJH (2001). Intestinal lymphatic drug uptake: an update. Adv Drug Delivery Rev 50: 61–80.

Driscoll MC (2002). Lipid based formulations for intestinal lymphatic delivery. Eur J Pharm Sci 15: 405– 415.

Ge H, Hu Y, Jiang X, Cheng D, Yuan Y, Bi H and Yang C (2002). Preparation and Evaluation of Poly(Ethylene Glycol)–Poly(Lactide) Micelles as Nanocarriers for Oral Delivery of Cyclosporine A. J Pharm Sci 91: 1463-1473.

Hu Y, Jiang X, Ding Y, Zhang L, Yang C, Zhang J, Chen J and Yang Y(2003). Preparation and drug release behaviors of Nimodipine-loaded poly(caprolactone)-poly(ethylene oxide)-polylactide amphiphilic copolymer nanoparticles. Biomaterials 24: 2395-2404.

Kapadia J, Shrivastava R and Ursekar B (2009). Design, Optimization, Preparation and Evaluation of Dispersion Granules of Valsartan and Formulation into Tablets. Current Drug Delivery 6: 28-37.

Kshirsagar SJ et al (2009). Dissolution improvement of poorly water soluble drug using dry emulsion and solid dispersion. J Pharm Res 2(10): 1780-1785.

Mader K and Mehnert W (2001). Solid lipid nanoparticles Production, characterization and applications. Adv Drug Delivery Rev 47: 165–196.

Manjunath K, Reddy JS and Venkateswarlu V (2005). Solid Lipid Nanoparticles as Drug Delivery Systems. Exp Clin Pharmacol 27(2): 1- 20.

Muller-Goymann CC and Schubert MA (2003). Solvent injection as a new approach for manufacturing lipid nanoparticles – evaluation of the method and process parameters. Eur J Pharm Biopharm 55: 125-131.

Polli JE, Rekhi GS, Augsburger LL and Shah VP (1997).Methods to compare dissolution profiles and a rationale for wide dissolution specifications for metoprolol tartrate tablets. J Pharm Sci 86: 690-700.

Satana E, Altinay S, Goger NG, Ozkan SA and Senturk Z (2001). Simultaneous determination of valsartan and hydrochlorothiazide in tablets by first-derivative UVspectrophotometry and LC. J Pharm Biomed Anal 25 (5–6): 1009 –1013.

Smith P (1996). Methods for evaluating intestinal permeability and metabolism in vitro. Pharm Biotech 13-34.

Song X, Zhao Y et al (2008). PLGA nanoparticles simultaneously loaded with vincristine sulfate and verapamil hydrochloride: Systematic study of particle size and drug entrapment efficiency. Int Journal Pharm 350: 320-329.